Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in GLUT1 DS
NCT02036853Phase 2Completed
- Sponsor
- Adrian Lacy
- Start
- Feb 2014
- Primary completion
- Jun 2019
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS) (2 arms), sponsored by Adrian Lacy. Primary endpoints: Reported Change in Seizures Frequency From Baseline at 5 years and Adverse Event Rates and Laboratory Values at 5 years. Started Feb 2014; status: completed.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on NCT02036853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036853.